JPWO2023032994A1 - - Google Patents

Info

Publication number
JPWO2023032994A1
JPWO2023032994A1 JP2023545611A JP2023545611A JPWO2023032994A1 JP WO2023032994 A1 JPWO2023032994 A1 JP WO2023032994A1 JP 2023545611 A JP2023545611 A JP 2023545611A JP 2023545611 A JP2023545611 A JP 2023545611A JP WO2023032994 A1 JPWO2023032994 A1 JP WO2023032994A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545611A
Other languages
Japanese (ja)
Other versions
JPWO2023032994A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023032994A1 publication Critical patent/JPWO2023032994A1/ja
Publication of JPWO2023032994A5 publication Critical patent/JPWO2023032994A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023545611A 2021-08-31 2022-08-30 Pending JPWO2023032994A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021141996 2021-08-31
PCT/JP2022/032639 WO2023032994A1 (ja) 2021-08-31 2022-08-30 化合物及びこれを用いた標識生体物質

Publications (2)

Publication Number Publication Date
JPWO2023032994A1 true JPWO2023032994A1 (https=) 2023-03-09
JPWO2023032994A5 JPWO2023032994A5 (https=) 2024-05-23

Family

ID=85411242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545611A Pending JPWO2023032994A1 (https=) 2021-08-31 2022-08-30

Country Status (5)

Country Link
US (1) US20240165240A1 (https=)
EP (1) EP4397671A4 (https=)
JP (1) JPWO2023032994A1 (https=)
CN (1) CN117642413A (https=)
WO (1) WO2023032994A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7787670B2 (ja) * 2021-08-31 2025-12-17 富士フイルム株式会社 化合物及びこれを用いた標識生体物質

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506522A (ja) * 1996-02-16 2000-05-30 サイトジェン・コーポレーション Ｓｈ３結合ペプチドの単離および利用
JP2003517300A (ja) * 1999-11-03 2003-05-27 アーツェーゲーテー プロゲノミクス アクチェンゲゼルシャフト 分子物質を結合させる方法
JP2003185655A (ja) * 2001-07-30 2003-07-03 Warner Lambert Co Llc プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP2019531474A (ja) * 2016-09-01 2019-10-31 ライフ テクノロジーズ コーポレーション 増強された蛍光のための組成物および方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5986694A (en) * 1992-12-30 1994-08-15 Baylor College Of Medicine Triplex forming oligonucleotides containing polymeric linkers
CA2423806C (en) 2000-09-29 2009-12-22 Molecular Probes, Inc. Modified carbocyanine dyes and their conjugates
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP2418284A1 (en) * 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
GB201220010D0 (en) 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
WO2015067302A1 (en) * 2013-11-05 2015-05-14 Ecole Polytechnique Federale De Lausanne (Epfl) Sensor molecules and uses thereof
KR101538268B1 (ko) 2014-03-06 2015-07-23 연세대학교 산학협력단 바이오마커 특이적 양친성 나노입자
JP6704404B2 (ja) * 2015-02-16 2020-06-03 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． ニコチンアミドアデニンジヌクレオチドを検出するためのセンサー、方法及びキット
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
RU2731211C1 (ru) 2017-03-21 2020-08-31 Фуджифилм Корпорэйшн Пептидное соединение и способ его получения, композиция для скринингового использования и способ отбора пептидного соединения
JP2019172826A (ja) 2018-03-28 2019-10-10 富士フイルム株式会社 蛍光性化合物及びこれを用いた蛍光標識生体物質
JP7064583B2 (ja) 2018-06-01 2022-05-10 富士フイルム株式会社 蛍光性化合物及びこれを用いた蛍光標識生体物質
EP3916000B1 (en) 2019-02-28 2026-04-08 FUJIFILM Corporation Method for producing peptide compound, protecting group-forming reagent, and aromatic heterocyclic compound
JP7344982B2 (ja) 2019-11-21 2023-09-14 富士フイルム株式会社 化合物及びこれを用いた蛍光標識生体物質
JP7394663B2 (ja) 2020-03-10 2023-12-08 グローリー株式会社 遊技情報閲覧システム
CN116419767A (zh) * 2020-08-18 2023-07-11 阿尔缇玛基因组学公司 用于标记生物分子的试剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506522A (ja) * 1996-02-16 2000-05-30 サイトジェン・コーポレーション Ｓｈ３結合ペプチドの単離および利用
JP2003517300A (ja) * 1999-11-03 2003-05-27 アーツェーゲーテー プロゲノミクス アクチェンゲゼルシャフト 分子物質を結合させる方法
JP2003185655A (ja) * 2001-07-30 2003-07-03 Warner Lambert Co Llc プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP2019531474A (ja) * 2016-09-01 2019-10-31 ライフ テクノロジーズ コーポレーション 増強された蛍光のための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 10, JPN6026007795, 1999, pages 241 - 245, ISSN: 0005807859 *
BIOCONJUGATE CHEM., vol. 14, JPN6026007793, 2003, pages 653 - 660, ISSN: 0005807858 *

Also Published As

Publication number Publication date
CN117642413A (zh) 2024-03-01
US20240165240A1 (en) 2024-05-23
EP4397671A1 (en) 2024-07-10
EP4397671A4 (en) 2025-02-19
WO2023032994A1 (ja) 2023-03-09

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303